Page 6 - Peter Greenleaf News Today

14.7 million in net revenue for the third quarter 2021 Steady increases in LUPKYNIS Patient Start Forms, Conversion Rates and Payer Coverage Addition of two preclinical assets with potential in rare autoimmune conditions to grow and diversify the pipeline Conference call to be hosted today at 8:30 a.m. ET Aurinia Pharmaceuticals Inc. today issued its financial results for the third quarter ended September 30, 2021. ...

AUPH earnings call for the period ending September 30, 2021.

Assets expand immunology portfolio to include B-cell therapy and macrophage modulation - - IND-enabling studies are ongoing and will support the transition of these assets to clinical development in 20222023 - Aurinia Pharmaceuticals Inc. today announced the addition of two novel assets that will expand the Company’s rare autoimmune and kidney-related disease pipeline. “Over the past year, in anticipation of ...

Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights Over 250 patient start forms received by the end of the first quarter – – Cash and cash equivalents, and investments of $360.9 million at March 31, 2021 – – Conference call to be hosted today at 5:00 p.m. ET – Aurinia Pharmaceuticals Inc. today issued its financial results for the first quarter ended March 31, 2021. Amounts, unless specified otherwise, are expressed in U.S. dollars. “2021 started ...

- Cash, cash equivalents, and investments of $423 million at December 31, 2020 - Victoria, BC, March 3, 2021--(T-Net)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) today issued its financial results for the fourth quarter and year ended December 31, 2020. Amounts, unless specified otherwise, are expressed in U.S. dollars. "Over the past year, Aurinia matured into a fully-integrated biopharmaceutical company with capabilities spanning R&D, clinical, regulatory, CMC, and commercial. T...

Operator Greetings, and welcome to the Aurinia Year-end 2020 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is recorded. Its now my pleasure to turn the call over to Glenn Schulman, Senior Vice President, Investor Relations. Please go ahead, sir. Glenn Schulman -- Senior Vice President, Corporate Communications and Investor Relations Thank you, Kevin, and good afternoon, everyone. Im pleased to welcome you to todays call discussing Aurinias fourth qua...

Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights LUPKYNIS TM is the first FDA-approved oral therapy for lupus nephritis a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death – – Cash, cash equivalents, and investments of $423 million at December 31, 2020 – – Conference call to be hosted today at 4:30 p.m. ET – Aurinia Pharmaceuticals Inc. today issued its financial res...

Feb 22, 2021 10:00am Beyond clinical and commercial manufacturing, Catalent also had a hand in developing the encapsulation process for Aurinia Pharmaceuticals drug Lupkynis. (Catalent) Just weeks after Aurinia Pharmaceuticals bagged its first FDA green light, the company is turning to one of its clinical manufacturing partners to help bring its drug to market.  Aurinia enlisted Catalent to deliver commercial supply of its oral lupus nephritis drug Lupkynis (voclosporin), the CDMO said Thurs...

Published: Dec 18, 2020 By Alex Keown Cidara Therapeutics – Christopher Kurtz was named executive vice president of Technical Operations at Cidara Therapeutics. Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development. Prior to joining Cidara, Kurtz served as head of commercial API manufacturing at Gilead Sciences. He previously served as vice presiden...

Aurinia Pharmaceuticals Inc.: Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan - Agreement includes royalties of up to 20 percent on net sales payable to Aurinia - Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH TSX:AUP) ("Aurinia" or the "Company") today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. for the development an...